JP2009540852A5 - - Google Patents

Download PDF

Info

Publication number
JP2009540852A5
JP2009540852A5 JP2009517228A JP2009517228A JP2009540852A5 JP 2009540852 A5 JP2009540852 A5 JP 2009540852A5 JP 2009517228 A JP2009517228 A JP 2009517228A JP 2009517228 A JP2009517228 A JP 2009517228A JP 2009540852 A5 JP2009540852 A5 JP 2009540852A5
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
antigen
nos
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009540852A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/056584 external-priority patent/WO2008003656A2/en
Publication of JP2009540852A publication Critical patent/JP2009540852A/ja
Publication of JP2009540852A5 publication Critical patent/JP2009540852A5/ja
Pending legal-status Critical Current

Links

JP2009517228A 2006-07-03 2007-06-29 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用 Pending JP2009540852A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81768606P 2006-07-03 2006-07-03
PCT/EP2007/056584 WO2008003656A2 (en) 2006-07-03 2007-06-29 Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics

Publications (2)

Publication Number Publication Date
JP2009540852A JP2009540852A (ja) 2009-11-26
JP2009540852A5 true JP2009540852A5 (enExample) 2010-08-05

Family

ID=38537749

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517228A Pending JP2009540852A (ja) 2006-07-03 2007-06-29 前立腺特異的な転写物ならびに前立腺癌の治療および診断におけるその使用

Country Status (10)

Country Link
US (1) US20120141376A1 (enExample)
EP (1) EP2044216A2 (enExample)
JP (1) JP2009540852A (enExample)
KR (1) KR20090111307A (enExample)
CN (1) CN101506376A (enExample)
AU (1) AU2007271232A1 (enExample)
CA (1) CA2656140A1 (enExample)
IL (1) IL196184A0 (enExample)
WO (1) WO2008003656A2 (enExample)
ZA (1) ZA200900794B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102439176B (zh) * 2009-05-12 2018-11-23 皇家飞利浦电子股份有限公司 用作恶性的、激素-敏感的前列腺癌的标志物的磷酸二酯酶4d7
DE102012203547A1 (de) * 2012-03-07 2013-09-12 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Antimikrobielle Peptide
EA036387B1 (ru) 2012-03-05 2020-11-03 Ой Арктик Партнерс Аб Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US11761962B2 (en) 2014-03-28 2023-09-19 Opko Diagnostics, Llc Compositions and methods related to diagnosis of prostate cancer
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
PL3253800T3 (pl) 2015-03-27 2021-08-23 Opko Diagnostics, Llc Standardy antygenów prostaty i ich zastosowanie
ES3007999T3 (en) * 2015-04-21 2025-03-21 Genentech Inc Compositions and methods for prostate cancer analysis
US10412939B2 (en) * 2015-09-02 2019-09-17 Regeneron Pharmaceuticals, Inc. Rodent model of prostate cancer
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
JP2022530100A (ja) * 2019-04-25 2022-06-27 アクティニウム ファーマシューティカルズ インコーポレイテッド 悪性および非悪性血液疾患の治療のための免疫枯渇の組成物および方法
CN111383757B (zh) * 2020-03-04 2023-08-25 南京亿科人群健康研究院有限公司 一种计算机辅助开发包虫病诊断试剂盒的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
WO1999043710A1 (en) * 1998-02-26 1999-09-02 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
CA2393002A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
AU2003242820A1 (en) * 2002-03-14 2003-09-22 Exonhit Therapeutics S.A. Variants of human kallikrein-2 and kallikrein-3 and uses thereof
US7834163B2 (en) * 2003-06-26 2010-11-16 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy

Similar Documents

Publication Publication Date Title
JP2009540852A5 (enExample)
JP2005504513A5 (enExample)
Gallotta et al. Inhaled TLR9 agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4+ and CD8+ T-cell interplay
JP2007537197A5 (enExample)
AU2019334261B2 (en) Process for preparing vaccine compositions
US20190345228A1 (en) Targeted therapeutic agents comprising multivalent protein-biopolymer fusions
JP2006515749A5 (enExample)
DK1759013T3 (da) Identificering af overflade-associerede antigener til tumordiagnose
JP2018509135A5 (enExample)
AU2015249374A1 (en) Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
JP2010516290A5 (enExample)
JP2009039107A5 (enExample)
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
JP2012520663A5 (enExample)
EP2227558A1 (en) Method for classifying cancer patients as responder or non-responder to immunotherapy
KR20210086612A (ko) 펩타이드 백신
RU2016138428A (ru) Пептиды neil3 и включающие их вакцины
KR20130055553A (ko) 환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법
KR20090016671A (ko) 레플리킨 펩티드 및 이의 용도
CN107551264B (zh) L3和/或l5源作为寄生虫病疫苗或诊断的用途
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof
CN102498219A (zh) 在得自对象的生物学样品中评价癌症的方法
KR101759401B1 (ko) 스핑크1 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
CN109468326A (zh) 一种cd4+t核酸适配体及其应用
EP2334826A2 (en) Method of detection and diagnosis of oral and nasopharyngeal cancers